News
![Lungs-16-9](https://pharmaphorum.com/wp-content/uploads/2016/07/Lungs-16-9.jpg)
Pliant seeks $250m offering on lung fibrosis data
Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised